Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial

Hepprich, Matthias; Mudry, Jonathan M; Gregoriano, Claudia; Jornayvaz, Francois R; Carballo, Sebastian; Wojtusciszyn, Anne; Bart, Pierre-Alexandre; Chiche, Jean-Daniel; Fischli, Stefan; Baumgartner, Thomas; Cavelti-Weder, Claudia; Braun, Dominique L; Günthard, Huldrych F; Beuschlein, Felix; Conen, Anna; West, Emily; Isenring, Egon; Zechmann, Stefan; Bucklar, Gabriela; Aubry, Yoann

doi:10.1016/j.eclinm.2022.101649

Citations

Citation copied

Hepprich, M., Mudry, J. M., Gregoriano, C., Jornayvaz, F. R., Carballo, S., Wojtusciszyn, A., Bart, P.-A., Chiche, J.-D., Fischli, S., Baumgartner, T., Cavelti-Weder, C., Braun, D. L., Günthard, H. F., Beuschlein, F., Conen, A., West, E., Isenring, E., Zechmann, S., Bucklar, G., … Donath, M. Y. (2022). Canakinumab in patients with COVID-19 and type 2 diabetes - A multicentre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine, 53, 101649. https://doi.org/10.1016/j.eclinm.2022.101649

Abstract

BACKGROUND: Patients with type 2 diabetes and obesity have chronic activation of the innate immune system possibly contributing to the higher risk of hyperinflammatory response to SARS-CoV2 and severe COVID-19 observed in this population. We tested whether interleukin-1β (IL-1β) blockade using canakinumab improves clinical outcome.

METHODS: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-of-care compared with placebo plus standard-of-care in patients